BRPI0900057A2 - processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos - Google Patents

processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos

Info

Publication number
BRPI0900057A2
BRPI0900057A2 BRPI0900057-7A BRPI0900057A BRPI0900057A2 BR PI0900057 A2 BRPI0900057 A2 BR PI0900057A2 BR PI0900057 A BRPI0900057 A BR PI0900057A BR PI0900057 A2 BRPI0900057 A2 BR PI0900057A2
Authority
BR
Brazil
Prior art keywords
von willebrand
willebrand factor
factor
concentrate
complex
Prior art date
Application number
BRPI0900057-7A
Other languages
English (en)
Inventor
Pere Ristol Debart
Tomas Maria Mercedes Faro
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39316136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0900057(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BRPI0900057A2 publication Critical patent/BRPI0900057A2/pt
Publication of BRPI0900057B1 publication Critical patent/BRPI0900057B1/pt
Publication of BRPI0900057B8 publication Critical patent/BRPI0900057B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

PROCESSO PARA A OBTENçãO DE UM CONCENTRADO DE FATOR DE VON WILLEBRAND OU DE UM COMPLEXO DE FATOR VIII/FATOR DE VON WILLEBRAND E USO DOS MESMOS. A presente invenção refere-se a um processo para a preparação de um concentrado de Fator de Von Willebrand ou de um complexo de Fator VIII/Fator de Von Willebrand e uso dos mesmos. O processo é caracterizado pela preparação de uma solução de Fator de Von Willebrand ou de um complexo de Fator VIII/Fator de Von Willebrand que contém VWF e uma concentração de até 12 IU de VWF:RCo/ml e uma razão de Fator de Von Willebrand /Fator VIII de 0,4 ou mais e então prosseguindo-se com a nanofiltração da solução preparada em a) através de um filtro que tem um tamanho de poro menor do que 35 nanometros.
BRPI0900057A 2008-01-08 2009-01-06 processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos BRPI0900057B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200800021 2008-01-08
ES200800021A ES2298096B1 (es) 2008-01-08 2008-01-08 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.

Publications (3)

Publication Number Publication Date
BRPI0900057A2 true BRPI0900057A2 (pt) 2009-09-22
BRPI0900057B1 BRPI0900057B1 (pt) 2021-03-23
BRPI0900057B8 BRPI0900057B8 (pt) 2021-06-29

Family

ID=39316136

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0900057A BRPI0900057B8 (pt) 2008-01-08 2009-01-06 processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos

Country Status (17)

Country Link
US (2) US8354505B2 (pt)
EP (1) EP2078730B9 (pt)
JP (1) JP4976366B2 (pt)
CN (1) CN101480490B (pt)
AR (1) AR072441A1 (pt)
AT (1) ATE509031T1 (pt)
AU (1) AU2008255137C1 (pt)
BR (1) BRPI0900057B8 (pt)
CA (1) CA2645701C (pt)
CL (1) CL2009000022A1 (pt)
ES (2) ES2298096B1 (pt)
HK (1) HK1129075A1 (pt)
MX (1) MX2008015892A (pt)
NZ (1) NZ573400A (pt)
PL (1) PL2078730T3 (pt)
PT (1) PT2078730E (pt)
RU (1) RU2417096C2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
JP5784907B2 (ja) * 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 組換え型ｖｗｆ製剤
TWI593421B (zh) 2008-10-21 2017-08-01 巴克斯歐塔公司 凍乾的重組ｖｗｆ調配物
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
WO2012176876A1 (ja) * 2011-06-24 2012-12-27 旭化成メディカル株式会社 蛋白製剤の製造方法
US11370827B2 (en) * 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
CN105705516B (zh) * 2013-11-08 2019-11-01 杰特有限公司 浓缩von Willebrand因子或其络合物的方法
DK3152230T3 (da) * 2014-06-06 2019-11-11 Octapharma Ag Præparat omfattende faktor viii og von willebrand-faktor-peptider
CN104804078B (zh) * 2015-05-05 2019-01-04 广东卫伦生物制药有限公司 人体血清凝血因子ⅷ中的病毒过滤方法
JP2020531516A (ja) * 2017-08-23 2020-11-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー フォン・ウィルブランド因子のウイルスろ過の方法
AU2022326188A1 (en) 2021-08-11 2024-02-22 Grifols Worldwide Operations Limited Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu

Also Published As

Publication number Publication date
JP4976366B2 (ja) 2012-07-18
HK1129075A1 (en) 2009-11-20
US20110275570A1 (en) 2011-11-10
NZ573400A (en) 2010-02-26
EP2078730A1 (en) 2009-07-15
ES2298096A1 (es) 2008-05-01
ES2298096B1 (es) 2009-01-01
AU2008255137B2 (en) 2011-04-07
CL2009000022A1 (es) 2009-11-20
EP2078730B9 (en) 2011-12-21
AU2008255137C1 (en) 2015-08-27
RU2008151957A (ru) 2010-07-10
BRPI0900057B1 (pt) 2021-03-23
CA2645701A1 (en) 2009-07-08
RU2417096C2 (ru) 2011-04-27
PL2078730T3 (pl) 2011-10-31
JP2009161528A (ja) 2009-07-23
CA2645701C (en) 2013-09-17
EP2078730B1 (en) 2011-05-11
MX2008015892A (es) 2009-07-07
PT2078730E (pt) 2011-07-14
AR072441A1 (es) 2010-09-01
ATE509031T1 (de) 2011-05-15
CN101480490A (zh) 2009-07-15
CN101480490B (zh) 2013-05-29
AU2008255137A1 (en) 2009-07-23
ES2363827T3 (es) 2011-08-17
US20090176709A1 (en) 2009-07-09
US8354505B2 (en) 2013-01-15
BRPI0900057B8 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
BRPI0900057A2 (pt) processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112014029716A2 (pt) remoção de fenol em processo de recuperação de paraxileno
BR112015005270A2 (pt) composições compreendendo peg e ascorbato
BR112015010915A2 (pt) conversor catalítico de três vias usando nano-partículas
AR059173A1 (es) Procedimiento para la obtencion de un etanol pobre en agua por deshidratacion con membranas y su empleo como educto en la elaboracion de etbe.
BR112012014791A2 (pt) processo para a preparação de uma peneira molecular contendo cobre com a estrutura de chabazita (cha), peneira molecular contendo cobre, catalisador, uso do catalisador, sistema de tratamento de gás de escapamento, e, método para reduzir seletivamente óxidos de nitrigênio nox.
RS20060169A (en) Process for preparing water soluble diterpens and their applications
BR112014029754B1 (pt) soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição
BR112014010704A2 (pt) processo para a preparação de uma dispersão de nanopartículas metálicas, dispersão de nanopartículas metálicas, bem como seu uso
BR112015012316A2 (pt) composições coletoras mistas
BRPI0513503A (pt) composições detergentes compreendendo partìculas coloridas
NO20083658L (no) Cyanoisokinolinforbindelser som stabiliserer hypoksi induserbar faktor(HIF)
BR112015006159A2 (pt) composição de revestimento de nanocelulose, seus usos e método para sua fabricação
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
BRPI0805397A2 (pt) modelo de equipamento de rotina de assento
TW200711719A (en) Use of 2,3-dihydroxynaphthalene-6-sulfonic acid salts as dispersants
BR112014013923A2 (pt) método para produção de mulita percolada num corpo de material, mulita percolada, uso da mulita percolada e corpo de material
PE20130728A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina
BR112017022971A2 (pt) aperfeiçoamentos em ou com relação a compostos orgânicos
BR112014016950A8 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BR102015012091A8 (pt) método para a preparação de uma solução de albumina humana, e, composição
BRPI0704030A (pt) uso de aluminas como massa de captura para complexos de silìcio organometálicos
NZ594118A (en) A dry powder composition for preventing or treating influenza comprising a lactose hydrate diluent and (2R,3R,4S)-3-acetamido-4-guanidino-2-[(1R,2R)-2-hydroxy-1-methoxy-3-(octanoyloxy)propyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
BR112014029874A8 (pt) composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2020 DE 22/09/2009, QUANTO AO ITEM (72)

B25G Requested change of headquarter approved

Owner name: GRIFOLS, S.A. (ES)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2620 DE 23/03/2021 QUANTO AO ENDERECO.